Jim Egan
- Sustained efficacy from 3 to 6 months following bronchoscopic thermal vapor ablation (BTVA) in the treatment of heterogeneous emphysemaBy Felix Herth, Gregory Snell, Peter Hopkins, Kim Baker, Christian Witt, Mark H. Gotfried, Arshang Valipour, Manfred Wagner, Franz Stanzel, Jim Egan, Steven Kesten and Armin ErnstFelix Herth1Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, GermanyGregory Snell2Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, AustraliaPeter Hopkins3Lung Transplant Unit, Prince Charles Hospital, Chermside, AustraliaKim Baker4Pulmonary and Critical Care Medicine, University of Iowa, Iowa City, United StatesChristian Witt5Pneumology, Charité Campus-Mitte, Berlin, GermanyMark H. Gotfried6Pulmonary Associates, John C. Lincoln Hospital, Phoenix, United StatesArshang Valipour7Ludwig-Boltzmann-Institute for COPD, Otto-Wagner-Hospital, Vienna, AustriaManfred Wagner8Pneumologie, Klinikum Nürnberg, Nürnberg, GermanyFranz Stanzel9Pneumologie, Zentrum für Pneumologie, Hemer, GermanyJim Egan10Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, IrelandSteven Kesten11Clinical Department, Uptake Medical Corp, Tustin, United StatesArmin Ernst12Pulmonary Critical Care and Sleep Medicine, Caritas St. Elizabeth's Medical Center, Boston, United States
- High resolution computed tomography (HRCT) measurements of lobar volume reduction associated with bronchoscopic thermal vapor ablation (BTVA) in patients with heterogeneous emphysemaBy Arschang Valipour, Felix J.F. Herth, Gregory Snell, Peter Hopkins, Kim Baker, Christian Witt, Mark H. Gotfried, Manfred Wagner, Franz Stanzel, Jim Egan, Steven Kesten and Armin ErnstArschang Valipour1Ludwig-Boltzmann-Institute for COPD, Otto-Wagner-Hospital, Vienna, AustriaFelix J.F. Herth2Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, GermanyGregory Snell3Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, AustraliaPeter Hopkins4Lung Transplant Unit, Prince Charles Hospital, Chermside, AustraliaKim Baker5Pulmonary & Critical Care Medicine, University of Iowa, Iowa City, United StatesChristian Witt6Pneumology, Charité Campus-Mitte, Berlin, GermanyMark H. Gotfried7Pulmonary Associates, John C. Lincoln Hospital, Phoenix, United StatesManfred Wagner8Pneumologie, Klinikum Nürnberg, Nürnberg, GermanyFranz Stanzel9Pneumologie, Zentrum für Pneumologie, Hemer, GermanyJim Egan10Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, IrelandSteven Kesten11Clinical Department, Uptake Medical Corp., Tustin, United StatesArmin Ernst12Pulmonary, Critical Care and Sleep Medicine, Caritas St. Elizabeth's Medical Center, Boston, United States
- Associations of efficacy outcomes following bronchoscopic thermal vapor ablation (BTVA) for the treatment of heterogeneous emphysemaBy Peter Hopkins, Felix J.F. Herth, Gregory Snell, Kim Baker, Christian Witt, Mark H. Gotfried, Arschang Valipour, Manfred Wagner, Franz Stanzel, Jim Egan, Steven Kesten and Armin ErnstPeter Hopkins1Lung Transplant Unit, Prince Charles Hospital, Chermside, AustraliaFelix J.F. Herth2Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg, Heidelberg, GermanyGregory Snell3Allergy Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, AustraliaKim Baker4Pulmonary and Critical Care Medicine, University of Iowa, Iowa City, IA, United StatesChristian Witt5Pneumology, Charité Campus-Mitte, Berlin, GermanyMark H. Gotfried6Pulmonary Associates, John C. Lincoln Hospital, Phoenix, AZ, United StatesArschang Valipour7Ludwig-Boltzmann-Institute for COPD, Otto-Wagner-Hospital, Vienna, AustriaManfred Wagner8Pneumology, Klinikum Nürnberg, Nürnberg, GermanyFranz Stanzel9Pneumologie, Zentrum für Pneumologie, Hemer, GermanyJim Egan10Advanced Lung Disease Program, Mater Misericordiae University Hospital, Dublin, IrelandSteven Kesten11Clinical Department, Uptake Medical Corp, Tustin, CA, United StatesArmin Ernst12Pulmonary Critical Care and Sleep Medicine, Caritas Ct. Elizabeth's Medical Center, Boston, MA, United States
- Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early single centre Irish experienceBy Peter Barry, Lorna Murphy, Majella Tuohy, Eoin Judge and Jim EganPeter Barry1Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, IrelandLorna Murphy1Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, IrelandMajella Tuohy1Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, IrelandEoin Judge1Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, IrelandJim Egan1Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland
- Fibrosis in emphysema: Radiologically occult but histologically prevalent process proportionate to smoking burdenBy Aurelie Fabre, Nazia Faheem, Jonathan Dodd, Maciek Narski, Ann Treacy, David Healy, Ian Lawrie, Thomas Finucane, Michael Keane, Jim Egan, Michael Tolan, Gilles Jebrak, Herve Mal and Marcus ButlerAurelie Fabre1Histopathology, St Vincent's University Hospital, Dublin, IrelandNazia Faheem1Histopathology, St Vincent's University Hospital, Dublin, IrelandJonathan Dodd2Radiology, St Vincent's University Hospital, Dublin, IrelandMaciek Narski3Thoracic Surgery, St Vincent's University Hospital, Dublin, IrelandAnn Treacy1Histopathology, St Vincent's University Hospital, Dublin, IrelandDavid Healy3Thoracic Surgery, St Vincent's University Hospital, Dublin, Ireland4National Lung Transplant Programme, Mater Misericordiae University Hospital, Dublin, IrelandIan Lawrie4National Lung Transplant Programme, Mater Misericordiae University Hospital, Dublin, IrelandThomas Finucane3Thoracic Surgery, St Vincent's University Hospital, Dublin, IrelandMichael Keane5Repiratory Medicine, St Vincent's University Hospital, Dublin, IrelandJim Egan4National Lung Transplant Programme, Mater Misericordiae University Hospital, Dublin, IrelandMichael Tolan3Thoracic Surgery, St Vincent's University Hospital, Dublin, Ireland4National Lung Transplant Programme, Mater Misericordiae University Hospital, Dublin, IrelandGilles Jebrak6Pneumologie, Hopital Bichat-Claude Bernard, Paris, FranceHerve Mal6Pneumologie, Hopital Bichat-Claude Bernard, Paris, FranceMarcus Butler5Repiratory Medicine, St Vincent's University Hospital, Dublin, Ireland
- The 2000 steps a day challenge: A tailored exercise programme for lung fibrosis patientsBy Nicola Cassidy, Irene Byrne and Jim EganNicola Cassidy1The Irish Lung Fibrosis Association, P.O. Box 10456, Blackrock, Dublin, IrelandIrene Byrne2The National Lung Transplant Unit, Mater Misericordiae University Hospital, Dublin, IrelandJim Egan2The National Lung Transplant Unit, Mater Misericordiae University Hospital, Dublin, Ireland
- The burden of idiopathic pulmonary fibrosis reported by patients and carers in IrelandBy Nicola Cassidy, Denise Dunne and Jim EganNicola Cassidy1Irish Lung Fibrosis Association, ILFA, Dublin, IrelandDenise Dunne1Irish Lung Fibrosis Association, ILFA, Dublin, IrelandJim Egan2National Lung Transplant Centre, Mater Misericordiae University Hospital, Dublin, Ireland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.